JP2022532865A5 - - Google Patents
Info
- Publication number
- JP2022532865A5 JP2022532865A5 JP2021564704A JP2021564704A JP2022532865A5 JP 2022532865 A5 JP2022532865 A5 JP 2022532865A5 JP 2021564704 A JP2021564704 A JP 2021564704A JP 2021564704 A JP2021564704 A JP 2021564704A JP 2022532865 A5 JP2022532865 A5 JP 2022532865A5
- Authority
- JP
- Japan
- Prior art keywords
- patient
- composition according
- grade
- administered
- neurotoxicity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025013168A JP2025069275A (ja) | 2019-05-03 | 2025-01-29 | キメラ抗原受容体免疫療法の投与方法 |
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962843190P | 2019-05-03 | 2019-05-03 | |
| US62/843,190 | 2019-05-03 | ||
| US201962855828P | 2019-05-31 | 2019-05-31 | |
| US62/855,828 | 2019-05-31 | ||
| US201962868262P | 2019-06-28 | 2019-06-28 | |
| US62/868,262 | 2019-06-28 | ||
| US201962931669P | 2019-11-06 | 2019-11-06 | |
| US62/931,669 | 2019-11-06 | ||
| US201962944903P | 2019-12-06 | 2019-12-06 | |
| US62/944,903 | 2019-12-06 | ||
| PCT/US2020/031231 WO2020227177A1 (en) | 2019-05-03 | 2020-05-03 | Methods of administering chimeric antigen receptor immunotherapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025013168A Division JP2025069275A (ja) | 2019-05-03 | 2025-01-29 | キメラ抗原受容体免疫療法の投与方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022532865A JP2022532865A (ja) | 2022-07-20 |
| JP2022532865A5 true JP2022532865A5 (enExample) | 2023-05-15 |
Family
ID=73050885
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021564704A Pending JP2022532865A (ja) | 2019-05-03 | 2020-05-03 | キメラ抗原受容体免疫療法の投与方法 |
| JP2025013168A Pending JP2025069275A (ja) | 2019-05-03 | 2025-01-29 | キメラ抗原受容体免疫療法の投与方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025013168A Pending JP2025069275A (ja) | 2019-05-03 | 2025-01-29 | キメラ抗原受容体免疫療法の投与方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20200384027A1 (enExample) |
| EP (2) | EP4249075A3 (enExample) |
| JP (2) | JP2022532865A (enExample) |
| KR (1) | KR20220005075A (enExample) |
| CN (3) | CN118593691A (enExample) |
| AU (2) | AU2020267378B2 (enExample) |
| BR (1) | BR112021021996A2 (enExample) |
| CA (1) | CA3138707A1 (enExample) |
| IL (1) | IL287533A (enExample) |
| MX (1) | MX2021013394A (enExample) |
| SG (1) | SG11202112123RA (enExample) |
| TW (1) | TW202108150A (enExample) |
| WO (1) | WO2020227177A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118593691A (zh) * | 2019-05-03 | 2024-09-06 | 凯德药业股份有限公司 | 施用嵌合抗原受体免疫疗法的方法 |
| WO2022117799A2 (en) * | 2020-12-04 | 2022-06-09 | Morphosys Ag | Anti-cd19 combination therapy |
| WO2022137186A1 (en) * | 2020-12-23 | 2022-06-30 | Crispr Therapeutics Ag | Cancer treatment using cd38 inhibitor and/or lenalidomide and t-cells expressing a chimeric antigen receptor |
| EP4271817A2 (en) | 2020-12-30 | 2023-11-08 | Alaunos Therapeutics, Inc. | Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof |
| CN113406334A (zh) * | 2021-06-02 | 2021-09-17 | 浙江省人民医院 | 一种dlbcl相关的生物标记组合物及其应用、dlbcl预后的效果预测模型 |
| JP7791305B2 (ja) * | 2021-07-30 | 2025-12-23 | カイト ファーマ インコーポレイテッド | 細胞療法により誘発された毒性の監視及び管理 |
| CN113786490A (zh) * | 2021-09-14 | 2021-12-14 | 华中科技大学同济医学院附属协和医院 | 能调控巨噬细胞表观遗传的制剂用于制备治疗噬血细胞综合征药物的应用 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5728388A (en) | 1989-10-03 | 1998-03-17 | Terman; David S. | Method of cancer treatment |
| US6319494B1 (en) | 1990-12-14 | 2001-11-20 | Cell Genesys, Inc. | Chimeric chains for receptor-associated signal transduction pathways |
| IL104570A0 (en) | 1992-03-18 | 1993-05-13 | Yeda Res & Dev | Chimeric genes and cells transformed therewith |
| WO1994009138A1 (en) | 1992-10-20 | 1994-04-28 | Cetus Oncology Corporation | Interleukin-6 receptor antagonists |
| US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
| US6406699B1 (en) | 1999-10-05 | 2002-06-18 | Gary W. Wood | Composition and method of cancer antigen immunotherapy |
| US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| KR20030032922A (ko) | 2000-02-24 | 2003-04-26 | 싸이트 테라피스 인코포레이티드 | 세포의 동시 자극 및 농축 |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| GB0700058D0 (en) | 2007-01-03 | 2007-02-07 | Scancell Aps | Anti-tumor vaccine based on normal cells |
| TWI440469B (zh) | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
| CN103459425B (zh) * | 2010-10-27 | 2015-11-25 | 安进研发（慕尼黑）股份有限公司 | 用于治疗dlbcl的组合物 |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| KR20140004174A (ko) | 2011-01-18 | 2014-01-10 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 암 치료를 위한 조성물 및 방법 |
| US9987308B2 (en) | 2011-03-23 | 2018-06-05 | Fred Hutchinson Cancer Research Center | Method and compositions for cellular immunotherapy |
| EP2532740A1 (en) | 2011-06-11 | 2012-12-12 | Michael Schmück | Antigen-specific CD4+ and CD8+ central-memory T cell preparations for adoptive T cell therapy |
| CN103946952A (zh) | 2011-09-16 | 2014-07-23 | 宾夕法尼亚大学董事会 | 用于治疗癌症的rna改造的t细胞 |
| WO2014055657A1 (en) | 2012-10-05 | 2014-04-10 | The Trustees Of The University Of Pennsylvania | Use of a trans-signaling approach in chimeric antigen receptors |
| AU2015214145A1 (en) | 2014-02-04 | 2016-08-25 | Kite Pharma. Inc. | Methods for producing autologous T cells useful to treat B cell malignancies and other cancers and compositions thereof |
| KR102349677B1 (ko) | 2015-05-28 | 2022-01-12 | 카이트 파마 인코포레이티드 | T 세포 요법을 위해 환자를 컨디셔닝하는 방법 |
| KR20180063320A (ko) | 2015-10-20 | 2018-06-11 | 카이트 파마 인코포레이티드 | T 세포 요법을 위한 t 세포를 제조하는 방법 |
| ES2986067T3 (es) | 2015-12-17 | 2024-11-08 | Novartis Ag | Moléculas de anticuerpos frente a PD-1 y usos de las mismas |
| SG11201900344YA (en) * | 2016-07-15 | 2019-02-27 | Novartis Ag | Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor |
| AU2018257894A1 (en) * | 2017-04-24 | 2019-10-31 | Kite Pharma, Inc. | Humanized antigen-binding domains against CD19 and methods of use |
| AU2018275894B2 (en) * | 2017-06-02 | 2025-04-24 | Juno Therapeutics, Inc. | Articles of manufacture and methods for treatment using adoptive cell therapy |
| AU2018345751A1 (en) * | 2017-10-02 | 2020-05-07 | Humanigen, Inc. | Methods of treating immunotherapy-related toxicity using a GM-CSF antagonist |
| MX421741B (es) * | 2017-10-18 | 2025-03-14 | Kite Pharma Inc | Inmunoterapia con receptores de antígeno quimérico y uso de la misma |
| CN118593691A (zh) * | 2019-05-03 | 2024-09-06 | 凯德药业股份有限公司 | 施用嵌合抗原受体免疫疗法的方法 |
-
2020
- 2020-05-03 CN CN202410645866.1A patent/CN118593691A/zh active Pending
- 2020-05-03 TW TW109114736A patent/TW202108150A/zh unknown
- 2020-05-03 BR BR112021021996A patent/BR112021021996A2/pt unknown
- 2020-05-03 JP JP2021564704A patent/JP2022532865A/ja active Pending
- 2020-05-03 EP EP23186520.5A patent/EP4249075A3/en active Pending
- 2020-05-03 WO PCT/US2020/031231 patent/WO2020227177A1/en not_active Ceased
- 2020-05-03 US US16/865,369 patent/US20200384027A1/en not_active Abandoned
- 2020-05-03 SG SG11202112123RA patent/SG11202112123RA/en unknown
- 2020-05-03 KR KR1020217039585A patent/KR20220005075A/ko not_active Ceased
- 2020-05-03 EP EP20801592.5A patent/EP3962490A4/en not_active Withdrawn
- 2020-05-03 CN CN202410645821.4A patent/CN118662516A/zh active Pending
- 2020-05-03 CA CA3138707A patent/CA3138707A1/en active Pending
- 2020-05-03 MX MX2021013394A patent/MX2021013394A/es unknown
- 2020-05-03 AU AU2020267378A patent/AU2020267378B2/en active Active
- 2020-05-03 CN CN202080043985.XA patent/CN114206346A/zh active Pending
-
2021
- 2021-10-24 IL IL287533A patent/IL287533A/en unknown
-
2023
- 2023-02-10 US US18/167,725 patent/US20230270785A1/en active Pending
-
2025
- 2025-01-29 JP JP2025013168A patent/JP2025069275A/ja active Pending
- 2025-04-30 AU AU2025203054A patent/AU2025203054A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022532865A5 (enExample) | ||
| JP2024156736A5 (enExample) | ||
| Liu et al. | PD-1/PD-L1 inhibitors in cervical cancer | |
| Antonia et al. | Immuno-oncology combinations: a review of clinical experience and future prospects | |
| Goldstein et al. | Drug-associated polymyalgia rheumatica/giant cell arteritis occurring in two patients after treatment with ipilimumab, an antagonist of ctla-4. | |
| Peng et al. | Chemotherapy induces programmed cell death-ligand 1 overexpression via the nuclear factor-κB to foster an immunosuppressive tumor microenvironment in ovarian cancer | |
| Lichtenegger et al. | Immunotherapy for acute myeloid leukemia | |
| JP2022078265A5 (enExample) | ||
| JP2019516748A5 (enExample) | ||
| Behnamfar et al. | Levonorgestrel-releasing intrauterine system (Mirena) in compare to medroxyprogesterone acetate as a therapy for endometrial hyperplasia | |
| CN115845070A (zh) | 用notch和pd-1或pd-l1抑制剂的组合治疗 | |
| JP2008515890A5 (enExample) | ||
| JP2018522851A5 (enExample) | ||
| JP2023521227A5 (enExample) | ||
| Cao et al. | Small-molecule compounds boost CAR-T cell therapy in hematological malignancies | |
| Lyons et al. | Bispecific T-cell engagers in childhood B-acute lymphoblastic leukemia | |
| JP2017537927A5 (enExample) | ||
| Duong et al. | T cell Immunoglobulin and mucin domain containing protein 3 (TIM-3) inhibitors in oncology clinical trials: a review | |
| Spies et al. | Prednisone chronotherapy | |
| MX2022001403A (es) | Metodos de administracion de anticuerpos anti-siglec-8 y corticosteroides. | |
| Nastoupil et al. | CELESTIMO: a phase III trial evaluating the efficacy and safety of mosunetuzumab plus lenalidomide versus rituximab plus lenalidomide in patients with relapsed or refractory follicular lymphoma who have received≥ 1 line of systemic therapy | |
| JPWO2020250915A5 (enExample) | ||
| JP2025072466A5 (enExample) | ||
| Diéras et al. | Phase I combining a P-glycoprotein inhibitor, MS209, in combination with docetaxel in patients with advanced malignancies | |
| CN113316449A (zh) | 胍那苄作为免疫疗法的佐剂 |